Adaptive BiotechnologiesADPT
Market Cap: 665M
About: Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
Employees: 709
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2023] → 2 (+1) [Q1 2024]
1.03% less ownership
Funds ownership: 99.19% [Q4 2023] → 98.16% (-1.03%) [Q1 2024]
7% less funds holding
Funds holding: 197 [Q4 2023] → 184 (-13) [Q1 2024]
18% less repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 68
33% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 39
35% less capital invested
Capital invested by funds: $704M [Q4 2023] → $457M (-$247M) [Q1 2024]
98% less call options, than puts
Call options by funds: $12K | Put options by funds: $581K
Research analyst outlook
4 Wall Street Analysts provided 1 year price forecasts over the past 6 months
4 analyst ratings
JP Morgan Rachel Vatnsdal | 11%upside $5 | Overweight Maintained | 8 May 2024 |
BTIG Mark Massaro | 11%upside $5 | Buy Maintained | 4 Apr 2024 |
Goldman Sachs Salveen Richter | 11%upside $5 | Neutral Maintained | 16 Feb 2024 |
JP Morgan Rachel Vatnsdal | 77%upside $8 | Overweight Maintained | 15 Feb 2024 |